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Abstract
Background: Helicobacter pylori is a crucial determining factor in the pathogenesis of benign and
neoplastic gastric diseases. Cyclooxygenase-2 (Cox-2) is the inducible key enzyme of arachidonic
acid metabolism and is a central mediator in inflammation and cancer. Expression of the Cox-2 gene
is up-regulated in the gastric mucosa during H. pylori infection but the pathobiological consequences
of this enhanced Cox-2 expression are not yet characterized. The aim of this study was to identify
novel genes down-stream of Cox-2 in an in vivo model, thereby identifying potential targets for the
study of the role of Cox- 2 in H. pylori pathogenesis and the initiation of pre- cancerous changes.
Results: Gene expression profiles in the gastric mucosa of mice treated with a specific Cox-2
inhibitor (NS398) or vehicle were analysed at different time points (6, 13 and 19 wk) after H. pylori
infection. H. pylori infection affected the expression of 385 genes over the experimental period,
including regulators of gastric physiology, proliferation, apoptosis and mucosal defence. Under
conditions of Cox-2 inhibition, 160 target genes were regulated as a result of H. pylori infection.
The Cox-2 dependent subset included those influencing gastric physiology (Gastrin, Galr1), epithelial
barrier function (Tjp1, connexin45, Aqp5), inflammation (Icam1), apoptosis (Clu) and proliferation
(Gdf3, Igf2). Treatment with NS398 alone caused differential expression of 140 genes, 97 of which
were unique, indicating that these genes are regulated under conditions of basal Cox-2 expression.
Conclusion: This study has identified a panel of novel Cox-2 dependent genes influenced under
both normal and the inflammatory conditions induced by H. pylori infection. These data provide
important new links between Cox-2 and inflammatory processes, epithelial repair and integrity.
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Background
Helicobacter pylori infection is associated with a variety of
gastric disorders including chronic gastritis, peptic ulcer
disease, mucosa associated lymphatic tissue (MALT) lym-
phoma, and gastric adenocarcinoma [1,2]. The patho-
genicity of the bacterium is determined by
epidemiological influences as well as bacterial and host
factors [1,3]. Bacterial colonization of the gastric mucosa
leads to development of a chronic inflammatory infiltrate,
which is accompanied by enhanced release of inflamma-
tory mediators, growth factors and reactive oxygen metab-
olites [2,4].
The inducible Cox-2 enzyme and its constitutively
expressed isoform Cox-1 are the key regulators of human
prostaglandin metabolism [5-7]. The end products of
their enzymatic activity comprise a panel of prostagland-
ins and thromboxanes, which have been identified as crit-
ical regulators of fundamental physiological and
pathological processes including platelet aggregation, par-
turition, T-cell development, inflammation and cancer [5-
7]. Cox-2 enzymatic activity is largely regulated through de
novo synthesis of Cox-2 protein [5,6].
In the stomach, enhanced Cox-2  expression has been
found during H. pylori-triggered gastritis as well as in
mucosal stress lesions, gastroduodenal ulcers and after
ischemia/reperfusion damage [8-10]. Cox-2 and its
related prostanoids also appear to contribute to the
pathogenesis of gastric cancer. Gastric adenocarcinoma
and premalignant mucosal lesions frequently over-
express the Cox-2 gene [11-14], and elevated intratumoral
Cox-2 levels seem to be associated with deeper tumor
invasion [15] and an increased frequency of lymphatic
metastasis [16]. In addition, Cox-2 inhibitors have been
demonstrated to potently suppress proliferation of
human gastric cancer cells in vitro [1,17,18] as well as
experimental gastric adenocarcinomas in nude mice [17].
Recently however, a number of reports have challenged
the notion that this anti- tumour activity is due to inhibi-
tion of Cox-2 itself [19]. Individuals taking Cox-inhibitors
have been reported to display a reduced risk for develop-
ment of gastric carcinoma [20], however the reported car-
diovascular side effects associated with chronic coxib
administration mean that clinical use of Cox- inhibitors
for anti-carcinogenic treatment is controversial (Reviewed
in[21]).
Expression of the Cox-2 gene therefore appears to be an
important step in the pathogenesis of benign and malig-
nant gastric diseases and therefore, clarification not only
of its contribution to H. pylori-dependent pathogenesis,
but also the downstream effects of Cox inhibiting drugs is
of special clinical significance.
We have previously demonstrated that H. pylori can
directly influence expression of Cox-2 in gastric epithelial
cells through transcriptional mechanisms, and identified
MAPK-ERK-dependent activation of a proximal cis-regula-
tory CRE-Ebox element as a key step in the H. pylori-
response of the Cox-2 gene [22]. While these results fur-
ther confirmed the pathophysiological link between the
bacterium and Cox-2, molecular effectors located down-
stream of Cox-2 during gastric H. pylori infection
remained unidentified.
Here we analysed gene expression in the gastric epithe-
lium of mice treated with the Cox-2 specific inhibitor
NS398, at different time points after H. pylori infection
using DNA microarrays and were able to define gene
expression profiles regulated by H. pylori through Cox-2-
dependent and independent mechanisms.
Results
Determination of Cox-2 inhibitor concentration
To determine the appropriate concentration of inhibitor
in our H. pylori infection model, PGE2 levels were meas-
ured in the gastric mucosa after H. pylori infection in the
presence or absence of Cox-2 inhibition with NS398.
Infected mice showed a 50% increase in PGE2 level in the
gastric mucosa. Treatment of infected mice with NS398
(10 mg/kg) led to a reduction in the PGE2 such that it did
not differ from the control group (data not shown). We
therefore concluded that a dose of 10 mg/kg was sufficient
to suppress Cox 2 activity in the presence of a H. pylori
infection.
Long term administration of the specific Cox-2 inhibitor 
NS398 does not significantly affect bacterial colonization 
or inflammatory scores
All mice in the infected groups were colonized with H.
pylori, as determined by quantitative culture. The bacterial
load increased only slightly in the period between 6 and
19 weeks (Figure 1A). Administration of NS398 did not
appear to have a significant effect on bacterial coloniza-
tion. Infection with H. pylori caused a low to middle grade
gastritis in infected mice that tended to increase in severity
over time, but did not lead to ulcer formation or evidence
of metaplasia (see Figure 1B, and Figure 1C for compari-
sons of mice in each group at week 13). These observa-
tions are in accordance with reports from other studies
where mice were infected for similar periods of time
[23,24]. Histological analysis showed administration of
vehicle and NS398 alone induces a low-grade gastritis
over time (Figure 1B).
RNA from animals with similar scores and colonization
levels (3 mice per group) were pooled and used to per-
form the three experimental comparisons: non-infected
versus infected (V vs V+Hp), infected versus NS398 treatedMolecular Cancer 2009, 8:22 http://www.molecular-cancer.com/content/8/1/22
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and infected (V+Hp vs NS398+Hp), and non-infected ver-
sus non-infected and NS398 treated (V vs NS398) (Figure
2A). The experiment was designed to enable us to deter-
mine gene expression profiles in the stomachs of mice
receiving vehicle alone or NS398 in vehicle, and to isolate
these from the effects of H. pylori infection.
Global gene expression in the gastric mucosa of H. pylori 
infected mice
The RNA used in this study was extracted from the gastric
mucosa only, and histological analyses of stomachs pre-
pared in this way have confirmed that muscle or other
connective tissue underlying the mucosa were not
included in our preparations (not shown). The changes in
gene expression seen in this study are therefore highly
likely to reflect a transcriptional response restricted to that
of gastric epithelial cells and the developing lymphocytic
and granulocytic infiltrates which characterise chronic H.
pylori infection. Cut-offs for significant changes in gene
expression were set at p < 0.05 and three fold change [25].
In H. pylori infected mice, 385 genes passed the cut- off cri-
teria at at least one time during the study (Figure 2A). H.
pylori infected mice that were treated with NS398 had 160
differentially expressed genes. In mice treated with NS398
alone, 140 genes were differentially expressed (Figure 2A).
Using a subtractive approach, genes were divided into
subgroups reflecting the major experimental effects: H.
pylori infection, Cox-2 suppression, and Cox-2 suppres-
sion during infection.
Infection with H. pylori induced a complex pattern of glo-
bal gene expression over the period of the experiment
(Figure 2B). Treatment of infected mice with NS398
resulted in a distinct gene expression signature, which was
additional to the effect of infection. Thirty-three of the
genes differently expressed in infected mice was a result of
NS398 treatment (red highlighted genes), in addition a
further 107 genes were only expressed in NS398 treated
and infected mice. In this manner a subgroup of genes
defined Cox-2 dependent genes was established. We sub-
divided these genes into subgroups to facilitate further
analysis based on the Gene Ontology categories using the
DAVID tool for gene annotation at the NCBI http://
david.abcc.ncifcrf.gov/. Table 1 contains selected Cox-2
dependent genes (a complete list may be found in Addi-
tional File 1, Table S2). Most genes showed a fluctuating
expression pattern indicating that control mechanisms
and the cumulative effects of both infection and Cox-2
suppression play a role in gene expression over time.
Effect of NS398 on gastric gene expression profiles
Previous studies on the Cox-2 inhibitor NS398 in a variety
of in vitro and in vivo models have demonstrated it is a spe-
cific inhibitor of Cox-2 activity with little or no influence
Administration of the specific Cox-2 inhibitor NS398 does  not significantly affect bacterial colonization or inflammatory  scores Figure 1
Administration of the specific Cox-2 inhibitor NS398 
does not significantly affect bacterial colonization or 
inflammatory scores. A. Treatment with NS398 does not 
influence H. pylori colonization in C57 BL/6 mice. CFU 
retrieved from the stomachs of individual mice at 6, 13 and 
19 weeks post infection (filled circles). B. Distribution of 
pathology scores in infected and control mice. Pathology was 
scored according to the Sydney system as follows: no inflam-
mation (0), low grade, non -active gastritis and low grade 
mild-active gastritis (1), middle grade mild active gastritis (2). 
C. Hematoxylin and Eosin stained paraffin sections from 13 
weeks post infection, representative images from non-
infected mice treated with vehicle only (V), non infected mice 
treated with NS398 (NS398), infected mice (V+Hp), and 
infected mice treated with NS398 (NS398+Hp). By week 13 
(17 weeks post-infection), moderate active gastritis was 
observed in both the V+Hp and NS398+Hp groups. Original 
magnification 20×, scale bar = 50 μm.Molecular Cancer 2009, 8:22 http://www.molecular-cancer.com/content/8/1/22
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Global gene expression in the gastric mucosa of mice infected with H. pylori Figure 2
Global gene expression in the gastric mucosa of mice infected with H. pylori. A. Venn diagram illustrating the break-
down of differentially expressed genes (more than 3 fold up or down) over the period of the study. The number of genes pass-
ing the cut-off criteria is indicated for each experimental comparison: Infected versus non-infected mice (V vs V+Hp), infected 
mice versus NS398 treated and infected mice (V+Hp vs NS398+Hp), and non-infected mice versus NS398 treated (V vs 
NS398). Numbers in parentheses represent the number total genes differently expressed in the three experimental compari-
sons. B. Trend plots representing global gene expression measured in the 3 experimental comparisons. Each point on the y-
axes represents the average expression ratio for genes passing the cut-off criteria at weeks 6, 13 and 19 after treatment starts, 
i.e. one line represents one gene. The 33 infection-related genes that were differently expressed as a result of NS398 treat-
ment are highlighted in red for all comparisons. Cox-2 (Ptgs2) is indicated by the yellow line.Molecular Cancer 2009, 8:22 http://www.molecular-cancer.com/content/8/1/22
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on the closely related, constitutively expressed Cox-1
[26,27]. In our study, long-term administration appeared
to have effects on gene expression that may have been
resolved or compensated for after several months, as a
large proportion of the genes which were up-regulated
after week 6 of administration were not differently
expressed after week 13 (Figure 2B and Table 1). Only 33
of the genes that were influenced by NS398 were also reg-
ulated in response to infection. A complete list of the
genes regulated as a result of NS398 treatment is shown
(Additional File 1, Table S3.
To complement the 'subtractive' method of classifying
genes, data were clustered using an unsupervised
approach. A self-ordering matrix (SOM) was created using
all Cox-2 dependent genes, Figure 3 shows an SOM plot
of the Cox2-dependent genes identified in the study (left
panel), the right panel shows a matrix of the same genes
to indicate the effect of H. pylori infection alone on the
same genes (See also Table 2). Broadly, the regulated
genes fell into the functional categories of being related to
epithelial barrier function, proliferation and maintenance
or inflammation (summarized in Figure 3B).
Confirmation of expression of selected Cox-2 dependent 
genes
The mean change in expression level of Cox1 (Ptgs1) and
Cox2 (Ptgs2), and a selection of Cox2-dependent genes
involved in inflammation (intracellular adhesion mole-
cule 1, Icam1; Transforming growth factor b1,Tgfb1), gas-
tric function (Gastrin, Gast), barrier function (Aquaporin
5, Aqp5; Tight junction protein 1, Tjp1) and proliferation/
carcinogenesis (Ornithine decarboxylase, Odc1) was
determined for individual mice at all time points by real-
time PCR (Additional File 1, Table S4). In 94% of cases
the change in expression could be confirmed (up- or
down- regulated over the three-fold cut off criteria).
In NS398 treated mice, the expression of Tjp1 dramatically
increased in the early stages of the study compared to
infected mice (Figure 3). The mouse EST homologous to
connexin 45 (AV148957, Gja7) was also decreased in
infected mice, regardless of NS398 treatment, as was a gas-
tric aquaporin Aqp5 (Figure 3). This suggested that Cox-2
inhibition has an effect on the H. pylori mediated influ-
ence of gastric barrier function, therefore we investigated
this further in an in vitro model. Western blot analysis
showed that infection with H. pylori also led to increases
in Zona occludens 1(ZO1, Human homologue to Tjp1)
protein expression in vitro in MKN28 gastric epithelial
cells, and that this increase was inhibited in the presence
of NS398 (Figure 4A). Interestingly, this effect was inde-
pendent of the presence of an intact type IV secretion sys-
tem, or the presence of the cytotoxin VacA, as H. pylori
deletion mutants also induced ZO1 expression (Figure
4B). Expression of ODC was decreased in MKN28 cells
treated with NS398 (Figure 4C), and was also independ-
ent of the presence of a functional type IV section appara-
tus or VacA.
Discussion
The aim of this study was to enhance our knowledge
about the role of cyclooxygenase-2 in H. pylori-triggered
mucosal inflammation by identifying new downstream
molecular effectors. The in vivo approach taken here has
also provided insight at the transcriptome level, into the
complex changes that occur as a result of the chronic
inflammatory response to H. pylori infection and to Cox-2
inhibition.
Both  H. pylori infection, and NS398 treatment elicited
unique transcriptional signatures in the gastric mucosa of
mice, despite the similarity in pathology scores and colo-
nization density between the different groups (Figure 1).
This is of interest because in another report employing a
Table 1: Experimental design
Week -4 & -3 0 6 13 19
Mice (n)
Vehicle only
(V)
17 Mock infection Treatment begin 5 6 6
NS398 (10 mg/kg)
(NS398)
17 Mock infection Treatment begin 5 6 6
Vehicle plus H. pylori (V+ Hp) 24 Infect SS1 Treatment begin 8 8 8
NS398 (10 mg/kg) plus H. pylori
(NS398+Hp)
24 Infect SS1 Treatment begin 8 8 8
After week 0 mice received daily sc. injections of NS398 or vehicle alone as indicated. Mice were killed at 6. 13 and 19 weeks after the start of 
treatment and H. pylori colonization (cfu), then pathology scores were determined and total RNA was prepared.Molecular Cancer 2009, 8:22 http://www.molecular-cancer.com/content/8/1/22
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model of mucosa-associated lymphoid tissue lymphoma
(MALT lymphoma), transcriptional profiles in BALB/c
mice infected with H. heilmannii were determined after 12
to 24 months, and the major changes in gene regulation
occurred in the earlier stages of the disease (<12 months,
mild to moderate pathology) [28]. After this time, cluster-
ing of the 300 most differentially expressed genes allowed
segregation of infected mice into groups corresponding
almost exactly with their pathological characterization. In
view of our data, we would conclude that during the early
Table 2: Fold change in gene expression of selected genes regulated as a result of infection with H. pylori and/or treatment with the 
specific Cox-2 inhibitor NS398
SYMBOL GENE NAME GENE ONTOLOGY V vs V + Hp V+Hp vs NS398+Hp V vs Ns398
61 3 1 9 6 1 31 961 3 1 9
Adn adipsin chymotrypsin, activity.
complement activation.
3.06 1.9 -1.32 -2.4 1.93 -1.07 -1.53 -2.56 -1.97
Akt3 thymoma viral proto-
oncogene 3
protein amino acid 
phosphorylation
-1.52 6.68 -1.02 -1.09 1.28 1.33 -1.44 -1.03 -1.06
AV148957 Connexin 45 water transport 1.39 -3.25 -1.04 1.29 -1.11 1.39 1 1.09 -1.01
Ccl5 chemokine (C-C motif) 
ligand 5
chemokine activity.
inflammatory response
1.23 -1.13 3.01 1.08 -1.13 -1.54 -1.21 1.48 1.08
Crpd. Dmbt1 deleted in malignant brain 
tumors 1/crp ductin, 
muclin
scavenger receptor 
activity.
tumor suppressor
4.15 -3.15 7.74 -2.64 -2.09 -2.15 1.78 1.28 -1
Gast gastrin hormone activity 6.37 -1.21 1.8 -8.41 -1.87 -1.01 1 -2.35 1.45
Hsp70-3 heat shock protein 1A chaperone activity 5.3 -1.86 1.31 -5.41 1.13 -1.15 3.23 -1.35 1.11
Icsbp1 interferon consensus seq. 
binding protein 1
immune response; 
transcription regulation
1 -1.31 3.36 1.19 1.23 -1.39 1 2.04 -1.37
Ifi47 interferon gamma 
inducible protein
ATP binding activity 1.3 -1.29 6.03 1.2 -1.13 -1.97 -1.85 -1.29 1.45
Ly75 lymphocyte antigen 75 defense response 1.23 -2.25 3.37 1.36 -1.15 1 1 1 1.39
Mup5 major urinary protein 5 pheromone binding 
activity; transport; 
transporter activity
4.94 -1.08 3 -6.56 -1.23 -2.5 7.56 -1.5 1.31
Ptgs1 prostaglandin-
endoperoxide synthase 1
prostaglandin biosynthesis -1.36 -1.03 -1.02 1.16 1.03 1 1.26 1.47 1.12
Ptgs2 prostaglandin-
endoperoxide synthase 2
prostaglandin biosynthesis 1.27 4.34 1.47 -1.02 1.17 1 -1.55 -1.24 -1.47
Odc Ornithine decarboxlyase carboxy- lyase activity 1.05 -1.69 -1.19 -1.34 -3.12 -1.11 1.94 -1.4 1.23
Slc7a11. cd98 light solute carrier family 7 
member 11. CD98 light
cationic amino acid 
transporter
1.37 3.42 1.19 1.09 2.24 1.33 -1.7 -1.64 -1.07
Tff1 trefoil factor 1 response to wounding -2.94 5.57 -3.06 -2.28 9.16 -1.56 -1.37 -6.56 2.84
Tgtp T-cell specific GTPase GTP binding activity 1.26 -1.24 8.29 1.55 -1.17 -2.72 -1.37 1.31 1.43
The Gene Ontology (GO) classification indicates gene function. A complete list of the expression level of all genes in the study may be found in 
Additional File 1, Tables S1-3.Molecular Cancer 2009, 8:22 http://www.molecular-cancer.com/content/8/1/22
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development phase of chronic active gastritis, standard
pathology analysis is not able to detect subtle, but impor-
tant changes in the mucosa.
NS398 specifically inhibits the activity of the Cox-2 pro-
tein, and alterations in Cox-2 gene expression might be
expected when infected mice were treated with a specific
Cox-2 inhibitor, either as a result of a possible feedback
mechanism involving PGE2 [29], or as a compensatory
mechanism to overcome the enzymatic inhibition. No
significant change in Cox-2 expression was observed in
vivo however, supporting the notion that the expression of
the Cox-2 gene in the stomach is controlled by a variety of
factors. Cox-2 is expressed by both inflammatory and gas-
tric epithelial cells [22] and its expression may be control-
led by different mechanisms in different cells types.
We were able to identify a subset of genes that were differ-
entially expressed as a result of Cox-2 suppression, high-
lighting the scope of influence of Cox-inhibitors in gastric
inflammation. Cox-2 dependent genes fell into numerous
functional categories, chiefly those involved in gastric
physiology (acid secretion, motility), epithelial repair and
proliferation, and inflammatory mediators.
Gastrin (Gast) is an important mediator in the stomach
[30-34] and expression in the mucosa was strongly influ-
enced, not only by infection with H. pylori, but also by
suppression of Cox-2 activity (Figure 3, Additional File 1,
Table S4). In addition to its role in regulating gastric acid
secretion, gastrin has trophic effects and regulates prolifer-
ation and repair in the mucosa. Indeed INS-GAS trans-
genic mice which suffer from hypergastrinemia develop
carcinoma after infection with H. pylori [35]. The develop-
ment of carcinoma is however restricted to males in this
model [35]. Other workers have also observed that Cox-2
inhibition influenced gastrin expression in an in vitro
colorectal cancer model [34] and also in H. pylori positive
gastric cancer patients [36].
Whereas expression of the apoptosis mediating growth
differentiation factor 3 (Gdf3) and c-Myc (Mycs) genes
peaked at week 13, the apoptosis inhibiting gene clusterin
(Clu) strongly decreased at this time point. Taken
together, the gene expression pattern is suggestive of a
shift in the rate of proliferation/apoptosis of the epithe-
lium after 13 weeks of infection as a result of NS398 treat-
ment. Longer-term studies would be required to
determine whether this effect continues or recurs. A
number of genes which have been previously observed to
be over-expressed in tumours (Mycs, Clu)[37], tumor sup-
pressors (Patched, Ptch), or otherwise involved in metas-
tasis or DNA repair: bikunin (Ambp)[38], ornithine
decarboxylase gene (Odc), Trefoil factor 1 (Tff1)[39], insu-
lin like growth factor (Igf2) [40] and DNA repair protein
Expression pattern of Cox-2 dependent genes Figure 3
Expression pattern of Cox-2 dependent genes. A. 
Two-dimensional self-ordering matrix (SOM) cluster show-
ing relative expression level of all Cox-2 dependent genes 
identified in this study (p > 0.05). Up- or down-regulations 
are indicated by red, or blue shading respectively. Black shad-
ing indicates similar gene expression in both samples. The 
right panel shows the cluster derived from the gene expres-
sion pattern in NS398 treated mice (V+Hp vs NS398+Hp). 
The left panel shows the expression of the same genes in 
infected mice (unclustered). Gene functions and literature 
references relevant to H. pylori infection are shown in Table 
3. Genes fitting the most prominent functional categories are 
highlighted with colour: proliferation/apoptosis (pale blue), 
epithelial integrity (orange), inflammatory response (red) and 
gastric physiology (green) B. Diagram summarizing the over-
all physiological effect of Cox-2 dependent genes over the 
period of the experiment, gene categories are coloured as in 
A.Molecular Cancer 2009, 8:22 http://www.molecular-cancer.com/content/8/1/22
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1 (Ddb1), were also differentially expressed in NS398
treated infected mice (Figure 3). The expression pattern
was complex however, and some mediators tended to be
enhanced by Cox-2 suppression, while the majority were
down-regulated (Figure 3). This probably reflects a regula-
tory role for Cox-2 as part of a network of control mecha-
nisms for epithelial maintenance. The Odc  gene, for
example, encodes a key regulatory enzyme in the produc-
tion of polyamines which are essential for cell prolifera-
tion [41] and has been shown to play a role alongside
Cox-2 in the development of atrophic gastritis [42,43]. It
has been proposed that Cox-2 inhibitors may inhibit Odc,
and in this way be responsible for the observed anti-pro-
liferative effects of Cox-2 inhibitors [44]. Our observation
of decreases in Odc expression as a result of NS398 treated
H. pylori infection in both in vivo and in vitro studies (Table
1 and Figure 4C) is in keeping with this notion.
Helicobacter  infection is strongly associated with the
induction of a strong Th1-type inflammatory response,
with high levels of Ifnγ, which induces expression of other
inflammatory mediators such as iNOS and Cox-2, and
also circulating growth factors such as gastrin [45]. Sup-
porting the notion that Ifnγ plays the key role in attracting
and activating lymphocytes [46,47], we observed that
expression of T-cell surface markers Icam1  [48,49] and
Cd86 and ligands (Sell) [50] peaked at week 13 in infected
mice. The interferon dependent GTPases (Igtp, Iigp-pend-
ing) regulate the anti-microbial activities of Ifnγ in a
STAT1 dependent manner [51,52], and their expression
was dramatically reduced in NS398 treated mice by the
end of the study. Overall, inhibition of Cox-2 activity led
to a reduced expression of inflammatory mediators
between weeks 13 and 19 (Figure 3); interestingly this
change was not reflected in the pathology scores. Cox-2
has been shown to modulate the Th1/Th2 balance in
inflammatory responses and inhibition of Cox-2 using
NS398 led to a polarization of the response of in vitro
stimulated human PBMCs toward Th1[53]. The authors
postulated that chronic expression of Cox-2 and produc-
tion of PGE2 results in an inhibition of the effectiveness
of the mucosal immune response by enhancing a state of
tolerance. The gene expression pattern we observed here is
indeed consistent with an effect of Cox-2 inhibition on
the inflammatory response (See Figure 3 and Table 1)
although the changes in expression of classical Th1/Th2
mediators such as IL-12, I-10 and IL-4 did not differ sig-
nificantly in our study.
Infection with H. pylori has been reported to damage epi-
thelial integrity and several potential mechanisms for this
have been reported (reviewed in [54]). CagA, a major H.
pylori pathogenicity factor, is translocated into epithelial
cells via the type IV secretion apparatus [55,56]. Studies in
a canine kidney cell model (MDCK) showed that CagA
associates with the tight junction adaptor protein zona
occludens 1 (zo-1, mouse homologue -tight junction pro-
tein 1, Tjp1) and the junctional adhesion molecule (Jcam
or Jam), leading to a long term disruption of epithelial
barrier function in vitro [57]. Whilst we observed
increased expression of Tjp1 at the transcriptional level in
NS398 treated infected mice, Jcam  expression was not
affected. In addition, an EST with homology to connexin
45 (AV148957, Gja7) and Aqp5 were influenced by H.
pylori infection regardless of NS398 treatment (Figure 3).
As both connexin 45 and Aqp5 are know to play a role in
intercellular transport of water and small molecules, and
there is experimental evidence that connexin 45 interacts
directly with Tjp1 [58,59], it would appear that Cox-2 also
has a role in the maintenance of water balance in the gas-
tric epithelium. This idea is supported by our in vitro
observations of a cox-2 dependent increase in Zo-1 pro-
tein expression in MKN28 cells. In contrast to the reports
by Amieva et al. [57] this effect was not related to the CagA
Cox-2 dependent expression of ZO1 and Ornithine decar- boxylase in MKN28 cells dependent in H. pylori infection Figure 4
Cox-2 dependent expression of ZO1 and Ornithine 
decarboxylase in MKN28 cells dependent in H. pylori 
infection. A. Expression of zona occludens-1 (ZO1) was 
determined by western blot at 6 h post infection in MKN28 
cells with either H. pylori wild type P12 or the isogenic 
mutants missing the entire cag PAI (PAI), or VacA (VacA). 
ZO1 was up regulated after infection, independent of CagA 
PAI or VacA (upper), whereas the expression was decreased 
in cells treated with NS398 (lower). B. Expression of Orni-
thine decarboxylase protein (ODC) was not affected by H. 
pylori infection, but was decreased in the presence of NS398.Molecular Cancer 2009, 8:22 http://www.molecular-cancer.com/content/8/1/22
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status of H. pylori (Figure 4). Barrier function effects in the
mouse model are in any case unlikely to be due to the
actions of CagA, as although we found that H. pylori SS1
expressed CagA protein, we were not able to detect trans-
location in either in vitro or in vivo experiments (data not
shown). Therefore, it would appear that H. pylori infection
has additional mechanisms to influence epithelial integ-
rity. It is also of note that another H. pylori pathogenicity
factor, vacuolating toxin (VacA) causes formation of fluid-
filled vacuoles in epithelial cells and furthermore, this
activity can be inhibited in vitro by NS398 treatment [60].
As the gastric aquaporin Aqp5 is expressed on the lateral
and intercellular membranes in the gastric crypts [59], we
speculate that this pore is influenced by changes to tight
junction proteins, and that it plays a role in the develop-
ment of oedema in the epithelium during infection.
A number of published reports have attempted to shed
light on gene regulation in H. pylori infection using the
microarray approach to study global gene expression in
gastric epithelial cells in vitro [61-63] (reviewed in [64]),
reporting a rapid up-regulation of inflammatory media-
tors and a variety of transcription factors to be the hall-
marks of the expression pattern. In our study, none of the
proliferation related genes (c-Fos, b-Fos, c-Jun and cyclinD1
(Pcna)) reported by Sepulveda et al., nor those reported by
Cox et al. (amphiregulin, Adam10) [61] were differentially
expressed in any group of mice. This probably reflects the
differences between the in vitro and  in vivo models of
infection. The data reported here, and that of other reports
[25,65] strongly suggest that cells of the immune system
influence not only this effect but also epithelial integrity,
limiting the conclusions that can be drawn from in vitro
studies using cell lines in isolation.
Conclusion
Some of the Cox-2 dependent genes from this study have
been previously identified as being influenced by Cox-2
or Cox-2 inhibition (Gast, Icam1, Odc), but the remainder
are novel and point to new links between Cox-2 and
inflammatory processes, epithelial repair and integrity.
This study has provided insights into not only the effects
of prostaglandin inhibitors on inflammation, but also
enabled us to identify novel Cox-2 dependent processes
such as a role in epithelial integrity and as a result further
targets for its role in transformation. Further investigation
of these targets will help us to explain the protective effects
of Cox-2 inhibitors and NSAIDs in gastritis patients and
aid the development of new treatment strategies.
Methods
H. pylori strains
H. pylori strain P12, ΔPAI and ΔVacA were cultured on GC
Agar plates as previously described [66,67]. The mouse
adapted H. pylori strain (SSI) (kind gift from A. Lee, Uni-
versity of Sydney, Australia) were cultured on GC Agar
plates as previously described [68]. For infection, bacteria
were scraped off plates and grown overnight in liquid cul-
ture in Brain Heart Infusion (BHI) broth [68].
Detection of prostaglandin E2 in stomach after daily 
administration of NS398
After infection with a single oral dose of 1 × 109 of a
mouse adapted strain of H. pylori (SS1) suspended in ster-
ile PBS, female C57 BL/6 mice (n = 18) then received daily
subcutaneous injections of either vehicle (1% Tween 80)
or 10 mg/kg of NS398 (Merck) in 1% Tween 80 for 14
days. On day 14, mice were euthanized and the stomach
was removed, opened, washed in ice cold PBS, and frozen
in liquid nitrogen. The gastric mucosa was scraped off and
pulverized in liquid nitrogen. The material was weighed,
suspended in 0.1 M phosphate buffer, vortexed for 1 min,
and then clarified by centrifugation at 10 000 g for 15 min
at 4°C. The supernatant was purified using a Prostaglan-
din E2 Affinity Column (Cayman) according to the man-
ufacturer's instructions. The amount of prostaglandin E2
was determined by enzyme immunoassay (PGE2 EIA kit;
Cayman).
Effect of administration of NS398 on inflammation in 
chronic H. pylori infection
For the long-term gene expression study, 48 female C57
BL/6 mice were infected with two oral doses (one week
apart) of 1 × 109 H. pylori (SS1) and 100 μl 0.1 M bicarbo-
nate. Control (non-infected) mice received bicarbonate
alone. Groups of infected and non-infected mice received
daily subcutaneous doses (100 μl) of 10 mg/kg NS398
dissolved in PBS, 1% Tween 80 for 6, 13 or 19 weeks. Con-
trol groups of mice received vehicle alone (PBS, 1% Tween
80) (Table 3).
Preparation of stomach tissue
Mice were killed and the stomach was removed and cut
along the greater curvature into two tissue fragments
encompassing antral and oxyntic mucosa, as well as part
of the non-secretory epithelium. The stomach was cut lon-
gitudinally into 3 parts. One third of the tissue was frozen
immediately in liquid N2. One third was weighed,
homogenized and then serially diluted and plated out on
Blood Agar plates (blood agar base No.2, 10% defibri-
nated horse blood, Vancomycin, Amphotericin B, Poly-
myxin B, Bacitracin, Nalidixic acid) to determine the
number of colony forming units (cfu) of H. pylori. The
remaining 1/3 of tissue was fixed in 4% buffered parafor-
maldehyde and processed for histological analysis. Tissue
was embedded in paraffin and 2–4 μm sections were
stained with hematoxylin and eosin, plus Warthin Starry
stain and assessed by 2 independent pathologists (M.S &
M.V) blinded to the experimental design. Pathology and
colonization were scored according to the modified Syd-
ney System [69].Molecular Cancer 2009, 8:22 http://www.molecular-cancer.com/content/8/1/22
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RNA isolation and quality control
RNA was isolated from 1/3 the gastric mucosa by scraping
tissue over liquid nitrogen as previously described [25].
RNA from 3 mice with similar colonization levels were
selected and pooled for microarray analysis.
In situ Oligonucleotide Arrays
A custom oligonucleotide glass array of specific 60 mer
oligonucleotides representing 8187 mouse genes was
designed based on Unigene Clusters (Unigene
build#148), and produced by Agilent Technologies (Palo
Alto, USA)[25]. Oligonucleotide probes were synthesized
Table 3: Function of selected Cox-2 dependent genes shown in Figure 3
Gene Function. Remarks Reference
Galr1 Receptor for galanin, pain perception, inhibits basal and gastrin-induced acid secretion
Tjp1 Tight junction protein, epithelial integrity. H. pylori interaction [57]
Gdf3 Regulator of cell growth and differentiation
Igf2 Cell growth/control [40]
Ifngr Inflammation [46]
Planh2.
Serpinb2
Inhibits plasminogen activator. important role in cell matrix degradation. gastrin dependent [32,30]
Ptch Cell fate. tumor suppressor
Mycs Oncogene. mediates apoptosis [37]
Tff1 Protects mucosa from insults. stabilizes mucus layer. epithelial healing. suppresses proliferation [39]
Iigp- pend.
& Igtp
Regulates anti-microbial activities of IFNγ in a STAT 1 dependent manner
Spi1-1-3 Tissue scavenger of leukocyte elastase
Aqp5 Water transport.
Gast Regulation of gastric acid secretion. Growth factor activity in gastric mucosa. Selective inhibition of Cox-2 reverses 
trophic activity.
[31,33,34]
Hspa1a Heat shock protein, chaperone.
Icam1 Mediates lymphocyte migration. [48,49]
Sell.
L-selectin
Mediates lymphocyte migration [50]
Clu Inhibits apoptosis, levels elevated in both mouse and human tumours
Ly64, MUC13 In concert with TLR4, controls B cell recognition and signalling of lipopolysaccharide (LPS)
Ambp, bikunin Suppresses urokinase expression and tumour metastasis [38]
Ddb1 DNA repair protein
Defcr Anti microbial peptide [25]
Literature references are shown for genes previously reported or investigated in connection with H. pylori infection.Molecular Cancer 2009, 8:22 http://www.molecular-cancer.com/content/8/1/22
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and deposited by Agilent using in situ ink-jet printing tech-
nology as proposed by Blanchard et al. [70].
Labeling and hybridization to arrays
RNA (5 μg) from each pool was amplified and labelled as
described previously [25]. Pairs of target RNAs were mixed
and hybridized to arrays to perform 3 experimental com-
parisons i.e. infected versus non infected, infected only
versus NS398 treated and infected and non infected versus
non infected and NS398 treated (Figure 2A). After data
extraction and normalization [25] data from duplicate
hybridizations were combined and expressed as log ratios
or fold changes. Statistical and bioinformatic analysis was
performed using the Rosetta Resolver™ software package
(V 3.2 (build 3.2.0.2.40)), Rosetta Biosoftware, Kirkland,
USA).
Culture of gastric cell lines, and in vitro infection 
experiments
MKN28 cells (ATCC, Rockville, USA) were cultured in
RPMI 1640 (Gibco BRL, Eggenstein, Germany) medium
containing 10% foetal calf serum (FCS, Invitrogen,
Carlsbad, Germany) using standard methods. H. pylori
strains P12, P12-PAI and P12-VacA were added to epithe-
lial cells at a multiplicity of infection (MOI) of 100. West-
ern blots were performed as described previously [22].
Proteins were transferred to a PVDF membrane (Perkin
Elmer, Jügesheim, Germany) and detected using specific
antibodies (Cox-2, Cayman, MI, USA; Zo1; Odc and
Aquaporin 5, Santa Cruz, CA, USA,). An HRP-labelled sec-
ondary goat anti-rabbit antibody was used (diluted
1:3000) and the Renaissance Western Blot system (ECL,
Eschwege, Germany) according to the manufacturer's rec-
ommendations.
Real-Time PCR assay
Total RNA was isolated from tissue as described above and
subsequently used for cDNA synthesis. Real-Time quanti-
tative RT-PCR analyses for Cox-2 sense 5'-AGA AGG AAA
TGG CTG CAG AA-3, antisense 5'AGG TGC TCG GCT
TCC AG TAT); Aqp5 sense 5'GGC CCT CTT AAT AGG CAA
CC-3, antisense 5'TTG CCT GGT GTT GTG TTG TT-3; Gast
sense 5' ACC AAT GAG GAC CTG GAA CA-3, antisense
5'CAT CCA TCC GTA TGC TTC CT-3; Tjp1 sense 5'-TCC
ACC TCT GTC CAG CTC TT-3', antisense 5'-CAC CGG
AGT GAT GGT TTT CT-3'; Icam1 sense, 5'-TTC ACA CTG
AAT GCC AGC TC-3' antisense 5'-GCC ACA GTT CTC
AAA GCA CA-3'; Odc sense 5'-TTG CCA CTG ATG ATT
CCA AA-3', antisense 5'-AGC CAC CAC CAA TAT CAA
GC-3' and TGFβ sense 5'-ACC TTC TGA TCC ATC GGT
TG-3' TGFβ antisense 5'-TTC CTG TTG GCT GAG TTG TG-
3' cDNA were performed using the ABM PRISM 7700
Sequence Detection System instrument and software (PE
Applied Biosystems, Inc., Foster City, CA) and SYBR
Green PCR Master mix (Applied Biosystems) with ther-
mocycler conditions recommended by the manufacturer.
PCRs were performed in duplicate in a total volume of 30
μl containing 10 μM primers. Data were normalized to
HPRT (hypoxanthine phosphoribosyl transferase) expres-
sion to perform relative quantifications (Primers: sense 5'-
GTT GGA TAC AGG CCA GCA TTT GT-3', antisense 5'-
CAC AGG ACT ACT AGA ACA CCT GC-3'). Relative gene
expression was calculated using the method described by
Pfaffl [71] and expressed as fold change.
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